Respiratory News and Research

RSS

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

First payments awarded from 9/11 compensation fund

Fifteen first responders received payments from a federal fund set up to compensate people who were sickened by the Sept. 11 terrorist attacks. So far, fewer applications have been received by the fund than officials estimated they would receive.

31 Jan 2013

GSU associate professor receives federal grant to bolster flu vaccine research

Sang-Moo Kang, associate professor at Georgia State University's Center for Inflammation, Immunity and Infection, has received a federal five-year, $3.4 million grant to bolster research that will lead to better flu vaccines and vaccines against respiratory syncytial virus (RSV), a disease for which there is no immunization.

31 Jan 2013

World Health Assembly's Executive Board concludes 132nd meeting

"The World Health Assembly's rotating Executive Board meets twice a year, and on 29 January concluded its 132nd meeting with what the WHO director general termed an 'unprecedented' amount of agenda items and documents," Intellectual Property Watch reports.

31 Jan 2013

ALDH1 expression predicts outcome in node-negative rectal cancer

Expression of the cancer stem cell marker aldehyde dehydrogenase 1 is an independent predictor for poor prognosis in node-negative rectal cancer, researchers say.

30 Jan 2013

Hospitalists flag patient overload threat to safety

Two-fifths of US hospitalists say their average patient load exceeds safe levels at least monthly, according to a nationwide survey.

30 Jan 2013

Achilles tendon lengthening shows benefits for diabetic foot

Researchers report that the addition of Achilles tendon lengthening to procedures for managing diabetic forefoot and midfoot ulceration seems warranted.

30 Jan 2013

TAPS supports preoperative transfusion

Preoperative transfusion may protect sickle cell patients from surgical complications, suggest findings published in The Lancet.

29 Jan 2013

High-frequency oscillatory ventilation put on hold

Findings from two trials suggest that high-frequency oscillatory ventilation does not help, and may even harm patients with acute respiratory distress syndrome.

29 Jan 2013

Building health insurance exchanges

News outlets report on small business concerns, the potential impact of immigration reform and how some medical device makers are passing on new fees to their customers.

29 Jan 2013

1 in 5 people infected with swine flu during first year of epidemic, WHO-led study shows

"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.

29 Jan 2013

Subcortical damage from craniotomies predicts neurologic deficits

Despite attempts to preserve cortical areas of function during awake craniotomy procedures, postoperative neurologic decline still occurs as a result of subcortical injury, report researchers.

28 Jan 2013

Shorter surveillance intervals detect HCC earlier

Hepatocellular carcinoma surveillance in at-risk patients at intervals of less than 6 months picks up smaller tumors compared with longer intervals, show two recently published studies.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

AstraZeneca, Orexo partner on OX-CLI preclinical program to treat respiratory diseases

Orexo AB announced today that the company has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.

28 Jan 2013

Less invasive treatment can provide superior survival to mastectomy in early stage breast cancer

Patients with early stage breast cancer who are treated with lumpectomy plus radiation have a better chance of survival compared with those who undergo mastectomy, according to Duke Medicine research.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Leading-edge Masimo medical devices to be displayed at Arab Health

Masimo returns to Arab Health Jan. 28-31, the world's longest running healthcare exhibition and congress held each year in Dubai, UAE, to showcase advanced, noninvasive patient monitoring technologies – including breakthrough SET Measure-Through Motion pulse oximetry and rainbow Pulse CO-Oximetry – that are becoming the standard-of-care across the Middle East.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013